Long-term clinical, virological and immunological consequences of mpox virus infection or modified vaccinia virus Ankara vaccination: a 24-month prospective cohort study.

BackgroundAs mpox virus (MPXV) continues to circulate, a better understanding of the long-term clinical, virological, and immunological consequences of infection and MVA-BN vaccination is needed. MethodsIn thiscohort study, we prospectively followed MPXV-infected individuals and individuals vaccinated with MVA-BN up to 24 months. Mpox patients were assessed for physical and mental well-being. Saliva and anorectal swabs were tested by MPXV-PCR. Vaccinia virus (VACV) lysate and MPXV-E8 binding and MPXV-neutralising antibodies were analysed over time, taking into account the impact of childhood smallpox vaccination. ResultsWe included 237 MPXV-infected individuals and 210 vaccinees; 93.9% (369/393) were gay or bisexual men who have sex with men, one-third (143/428, 33.4%) lived with HIV, and 31.8% (142/447) were born before or in 1976, (end of smallpox vaccination in Belgium). Scarring occurred in 31.7% (20/63) up to two years post-infection. MPXV was not detected [&ge;]8 months post-infection. Without childhood smallpox vaccination, MVA-BN vaccinees had significantly lower binding antibody levels than MPXV-infected individuals (0.39-fold, 95%CI 0.27-0.55, p<.001 for VACV-lysate antibodies, and 0.60-fold, 95%CI 0.46-0.79, p<.001 for MPXV-E8 antibodies). MPXV-E8 antibody levels decreased most rapidly over time in smallpox-naive MVA-BN vaccinees (-8%/month, 95%CI -9.09 to -7.42). MPXV-neutralising antibodies were rarely detected in smallpox-naive MVA-BN vaccinees (estimated seroprevalence 3%, 95%CI 1-11%, i.e. 0.04-fold, 95%CI 0.01-0.12, p<.001 lower compared to smallpox-naive MPXV-infected individuals). DiscussionLower antibody levels among MVA-BN vaccinees compared to MPXV-infected individuals suggest a less robust immunological priming induced by vaccination. Studies should assess if booster doses enhance the durability of the immunological memory. FundingResearch Foundation-Flanders; Department of Economy, Science and Innovation Flanders; Netherlands Organization for Health Research and Development (ZonMw)